Changes in foveal thickness after vitrectomy for macular edema with branch retinal vein occlusion and intravitreal vascular endothelial growth factor.
Purpose To examine the outcome of vitrectomy for macular edema associated with branch retinal vein occlusion (BRVO) and determine the relationship between the severity of macular edema and the concentration of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) in the vitreous fluid. Design Prospective observational case series. Patients and Methods Thirty-four consecutive patients (34 eyes) with macular edema associated with BRVO underwent vitrectomy. Retinal thickness was examined using optical coherence tomography. VEGF and IL-6 levels in the vitreous fluid were determined by enzyme-linked immunosorbent assay. The patients were followed for 6 months and longer after surgery. Results Visual acuity and the retinal thickness at 6 months after operation were significantly improved (P = 0.0042 and P < 0.0001, respectively). There was a significant positive correlation between the vitreous levels of VEGF and improved level of the severity of macular edema. The vitreous levels of VEGF were significantly higher in patients who showed greater improvement in the severity of macular edema (r = 0.4277, P = 0.0116). The vitreous levels of IL-6 were not significantly correlated with improvement in the severity of macular edema (r = 0.1996, P = 0.2578). Conclusion Vitrectomy appears effective for treatment of macular edema with BRVO. A higher VEGF level in the vitreous fluid may be associated with greater improvement of macular edema with BRVO.
Yamasaki
Makiko
M
Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. earth-yama@umin.net
Noma
Hidetaka
H
Funatsu
Hideharu
H
Minamoto
Atsushi
A
Mimura
Tatsuya
T
Shimada
Katsunori
K
Yamashita
Hidetoshi
H
Kiuchi
Yoshiaki
Y
D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood / Q000378:metabolism; D005260:Female; D005584:Fovea Centralis / Q000473:pathology*; D006801:Humans; D015850:Interleukin-6 / Q000096:biosynthesis / Q000097:blood; D008269:Macular Edema / Q000209:etiology / Q000378:metabolism* / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D015356:Retinal Artery Occlusion / Q000150:complications*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis* / Q000097:blood; D014792:Visual Acuity; D014821:Vitrectomy; D014822:Vitreous Body / Q000378:metabolism*
D015415:Biomarkers; D015850:Interleukin-6; D042461:Vascular Endothelial Growth Factor A
Am J Ophthalmol. 1984 Sep 15;98(3):271-82
6383055
Trans Am Acad Ophthalmol Otolaryngol. 1974 Mar-Apr;78(2):OP178-92
4825043
Science. 1983 Feb 25;219(4587):983-5
6823562
Am J Ophthalmol. 1999 Jun;127(6):688-93
10372879
Graefes Arch Clin Exp Ophthalmol. 2001 Oct;239(10):729-32
11760031
Invest Ophthalmol Vis Sci. 2000 Mar;41(3):877-9
10711707
Doc Ophthalmol. 1999;97(3-4):465-9
10896365
Am J Ophthalmol. 2000 Apr;129(4):487-94
10764858
Ophthalmology. 1996 Nov;103(11):1820-8
8942877
J Biol Chem. 1996 Jan 12;271(2):736-41
8557680
Ophthalmology. 2003 Sep;110(9):1690-6
13129863
Endocrinology. 1992 Aug;131(2):710-4
1639018
Trans Am Acad Ophthalmol Otolaryngol. 1974 Mar-Apr;78(2):OP166-77
4825042
Arch Ophthalmol. 1986 Jan;104(1):34-41
2417579
Ophthalmology. 2001 Feb;108(2):372-6
11158815
Am J Ophthalmol. 2002 Jan;133(1):70-7
11755841
Am J Ophthalmol. 2005 Aug;140(2):256-61
16086947
Graefes Arch Clin Exp Ophthalmol. 2006 Mar;244(3):309-15
16133018
Surv Ophthalmol. 2004 Sep-Oct;49(5):470-90
15325193
Glia. 1998 Oct;24(2):216-25
9728767
Am J Ophthalmol. 1985 Feb 15;99(2):218-9
4038586